Dr Reddy's Laboratories said it is delaying commercial supplies of semaglutide due to an active pharmaceutical ingredient (API) issue, which weighed on shares. The timing disruption is expected to pressure near-term sales while remediation is underway.
Dr Reddy's Laboratories said it is delaying commercial supplies of semaglutide due to an active pharmaceutical ingredient (API) issue, which weighed on shares. The timing disruption is expected to pressure near-term sales while remediation is underway.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
